recent approach found no associations between depression and SCZ PRS and response to antidepressants (Garcia-Gonzalez et al., 2017) among 3756 treatment receiving patients. Further, pharmacogenomics GWAS (i.e., the study of treatment response) have consistently revealed larger effects (OR 2.5) than studies of disorder, even when comparing sample size-matched studies (Maranville and Cox, 2016). Thus, the genetics of treatment response, much like the genetics underlying interaction with the environment, may be, at least partially, distinct from the genetics of disorder liability and require its own PRS to have clinical implications.
